What is the mechanism of action of this treatment?

Common cancer treatments often involve enzyme inhibition, which is crucial for targeting specific pathways that cancer cells use to grow and survive. Cabozantinib, a tyrosine kinase inhibitor, blocks enzymes involved in tumor growth and angiogenesis, thereby starving the tumor of nutrients and inhibiting its growth. Pamiparib, a PARP inhibitor, prevents cancer cells from repairing DNA damage, leading to cell death. These targeted therapies are significant for cancer patients as they offer the potential for more effective treatments with fewer side effects compared to traditional chemotherapy, improving overall outcomes and quality of life.

What side effects are associated with this type of intervention?

Enzyme inhibition treatments for cancer, such as Cabozantinib and Pamiparib, commonly cause a range of side effects. These can include fatigue, nausea, diarrhea, decreased appetite, and hyperglycemia. More severe adverse events may involve increased levels of amylase and lipase, anemia, and decreased neutrophil counts. While these treatments can be effective in halting tumor growth, patients often experience significant treatment-related toxicity that requires careful management.

What prior FDA approvals exist?

Several enzyme inhibitors have received FDA approval for cancer treatment. Tyrosine kinase inhibitors like cabozantinib, which targets multiple kinases including MET, VEGFR, and RET, are approved for various cancers such as medullary thyroid cancer and renal cell carcinoma. Other similar drugs include vandetanib and lenvatinib. PARP inhibitors like pamiparib, which inhibit the enzyme poly (ADP-ribose) polymerase, are used in cancers with BRCA mutations. FDA-approved PARP inhibitors include olaparib, rucaparib, and niraparib, which are used for ovarian, breast, and prostate cancers. These drugs work by blocking enzymes essential for DNA repair, thereby preventing cancer cell growth.

What other types of research exist?

Promising alternatives to Cabozantinib and Pamiparib for cancer treatment in 2024 include Niraparib, Olaparib, Selpercatinib, Infigratinib, Pembrolizumab, and Nivolumab. These therapies have shown efficacy in clinical trials for various advanced or refractory cancers.

← Back to Search

Tyrosine Kinase Inhibitor

Cabozantinib + Pamiparib for Advanced Cancer

Phase 1

Recruiting

Led By Siqing Fu

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must have one of the specified genetic and pathologic features as defined in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory

Patients must be able to take oral medications without medical history of malabsorption or other chronic gastrointestinal disease

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 6 months

Awards & highlights

Study Summary

This trial finds the best dose and side effects of cabozantinib and pamiparib in treating patients with advanced or refractory solid tumors.

Who is the study for?

Adults with advanced solid tumors that are resistant to standard treatments or have no standard treatment options available. Participants must have specific genetic markers related to tumor growth, be able to take oral medication, and not have had certain recent treatments. They should also meet various health criteria like adequate blood cell counts and organ function, agree to use effective contraception, and not be pregnant or breastfeeding.Check my eligibility

What is being tested?

The trial is testing the combination of two drugs, Cabozantinib and Pamiparib, for their effectiveness in stopping tumor growth by inhibiting enzymes needed for cell proliferation. It aims to determine the optimal dosages and document any side effects when used together on patients with refractory advanced solid tumors.See study design

What are the potential side effects?

Potential side effects may include but are not limited to fatigue, digestive issues such as nausea or diarrhea, changes in blood pressure or heart rhythm disturbances (QTc prolongation), liver enzyme alterations indicating potential liver damage, possible bleeding complications if taking anticoagulants concurrently, and increased risk of infection.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My condition has a specific genetic feature confirmed by a certified lab.

Select...

I can take pills and do not have chronic stomach or absorption problems.

Select...

I am fully active or restricted in physically strenuous activity but can do light work.

Select...

I am willing to provide tissue samples for the study.

Select...

I have not been treated with drugs that target PARP and VEGF at the same time.

Select...

My cancer can be measured or seen on scans.

Select...

I am 18 years old or older.

Select...

I haven't had radiation aimed at relieving symptoms on my only cancer spots during the study.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dose-limiting toxicities

Incidence of adverse events

Recommended phase 2 dosage

Side effects data

From 2022 Phase 2 trial • 45 Patients • NCT02101736

95%

HYPOTHYROIDISM

73%

DIARRHEA

55%

WEIGHT LOSS

50%

FATIGUE

41%

NAUSEA

41%

ASPARTATE AMINOTRANSFERASE INCREASED

41%

VOMITING

41%

ANOREXIA

41%

ALANINE AMINOTRANSFERASE INCREASED

41%

Neutrophil Count Decreased

36%

PAIN IN EXTREMITY

36%

HEADACHE

36%

PALMAR-PLANTAR ERYTHRODYSESTHESIA SYNDROME

36%

HYPERTENSION

32%

PAIN

32%

PROTEINURIA

27%

ABDOMINAL PAIN

27%

White Blood Cell Count Decreased

23%

Platelet Count Decreased

23%

Skin Hypopigmentation

23%

HAIR COLOR CHANGE

23%

Renal & Urinary Disorders - Other, Ketonuria

23%

PLATELET COUNT DECREASE

23%

HYPONATREMIA

23%

Decreased Platelet Count

18%

HYPOPHOSPHATEMIA

18%

HYPOKALEMIA

18%

Alopecia

18%

Hyperkalemia

18%

Upper Respiratory Infection

18%

HEMOGLOBIN INCREASED

14%

BILIRUBIN INCREASED

14%

DIZZINESS

14%

Pruritis

14%

ACNEIFORM RASH

14%

Fever

14%

Rash Maculopapular

14%

CONSTIPATION

14%

HYPERGLYCEMIA

14%

HYPOGLYCEMIA

14%

Blood Bilirubin Increased

14%

Cough

14%

Rash Acneiform

14%

Skin And Subcutaneous Disorders - Other, Achromotricia

ORAL PAIN

ALKALINE PHOSPHATASE INCREASED

TUMOR PAIN

WEIGHT GAIN

NASAL CONGESTION

Skin And Subcutaneous Tissue Disorders- Other, Rash Unspecified

ABSOLUTE NEUTROPHIL COUNT DECREASED

LIPASE INCREASED

LYMPHOCYTE COUNT DECREASED

HYPOCALCEMIA

DRY SKIN

Back Pain

Creatinine Increased

Papulopustular Rash

Paresthesia

Investigations - Other, Eosinophilia

Surgical & Medical Procedures - Other, Dental Extractions

INSOMNIA

SPINAL CORD COMPRESSION

Hypertension

ANXIETY

Sore Throat

Myalgia

Peripheral Sensory Neuropathy

Peripheral Motor Neuropathy

SINUS BRADYCARDIA

Hoarseness

SUBJECT WAS ADMITTED TO THE HOSPITAL ON 10/24/20 WITH GRADE 2 WEIGHT LOSS THAT THE PHYSICIAN FELT NE

RASH

Stomach Pain

HEMATURIA

Gastrointestinal Disorders - Other, Dental Pain

TENDONITIS

HYPERTHYROIDISM

Gastrointestinal Disorders - Other, Buccal Cyst

Musculoskeletal And Connective Tissue Disorder - Other, Tendinitis

Musculoskeletal And Connective Tissue Disorders - Other, Extremity Cramps

DIFFICULTY WALKING, BACK PAIN, BOWEL/BLADDER URGENCY, LEGS GAVE OUT, AND PARESTHESIAS

Gastrointestinal Disorders - Other, Stomatitis

Facial Pain

HYPOMAGNESEMIA

Allergic Rhinitis

Activated Partial Thromboplastin Time Prolonged

Leg Pain

Muscle Weakness Lower Limb

Muscle Weakness Upper Limb

Psychiatric Disorders - Other, Mood Swings

Scalp Lesion

Scalp Pain

Sinus Tachycardia

Sinusitis

Skin And Subcutaneous Tissue Disorders- Other, Blister/Bug Bite On Finger

Skin And Subcutaneous Tissue Disorders- Other, Erythema

Skin And Subcutaneous Tissue Disorders- Other, Sore On Lips

Skin And Subcutaneous Tissue Disorders- Other, Transient Erythema

Syncope

Tachycardia

Urine Discoloration

JOINT RANGE OF MOTION DECREASED

ANEMIA

PARONYCHIA

BRUISING

SERUM AMYLASE INCREASED

SKIN INFECTION

HYPOALBUMINEMIA

URINARY FREQUENCY

URINARY URGENCY

Behaviour Disturbance

Breast Pain

Conjunctivitis

Creatine Phosphokinase Increased

Ear And Labyrinth Disorders - Other, Impacted Cerumen

Ear Pain

Elevated Amylase

Hypermagnesemia

Hypotension

Infections And Infestations - Other, Covid-19

Infections And Infestations - Other, Gi Viral Infection

Injury, Poisoning And Procedural Complications - Other, Ankle Injury

Injury, Poisoning And Procedural Complications- Other, Scalp Laceration

Investigations - Other, Increased Mean Corpuscular Volume

Investigations - Other, International Normalized Ration Increased

Laryngitis

Localized Edema

Lung Infection

Metabolism And Nutrition Disorders - Other, Decreased Oral Intake

Metabolism Other - Decreased Vitamin D

Metbolism And Nutrition Disorders - Other, Hyperchloremia

Mucositis Oral

Neuropathy

Periodontal Disease

Rash Ezcematoid

Skin And Subcutaneous Disorders - Other, Dry Skin Patches

Skin And Subcutaneous Tissue Disorders - Other, Skin Color Change

Skin And Subcutaneous Tissue Disorders - Other: Blue Lips (Not Cyanosis)

Skin And Subcutaneous Tissue Disorders- Other, New Freckles/Moles

Tooth Infection

Joint Range Of Motion Decreased

100%

80%

60%

40%

20%

Study treatment Arm

Cohort B

Cohort A

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (cabozantinib, pamiparib)Experimental Treatment2 Interventions

Patients receive cabozantinib PO QD and pamiparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cabozantinib

2020

Completed Phase 2

~1760

Pamiparib

2017

Completed Phase 2

~750

0 / 8Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common cancer treatments often involve enzyme inhibition, which is crucial for targeting specific pathways that cancer cells use to grow and survive. Cabozantinib, a tyrosine kinase inhibitor, blocks enzymes involved in tumor growth and angiogenesis, thereby starving the tumor of nutrients and inhibiting its growth. Pamiparib, a PARP inhibitor, prevents cancer cells from repairing DNA damage, leading to cell death. These targeted therapies are significant for cancer patients as they offer the potential for more effective treatments with fewer side effects compared to traditional chemotherapy, improving overall outcomes and quality of life.

Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.Inference of synergy/antagonism between anticancer drugs from the pooled analysis of clinical trials.New and emerging combination therapies for esophageal cancer.